International consensus on severe lung cancer—the first edition
Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Feng Ye(First Affiliated Hospital of Xiamen University), Weifeng Li(Guangdong Academy of Medical Sciences), Yong He(Army Medical University), Xiaoqun Ye(Nanchang University), Yinyin Qin(First Affiliated Hospital of Guangzhou Medical University), Xinqing Lin(First Affiliated Hospital of Guangzhou Medical University), Xiuyu Cai(Sun Yat-sen University), Shengxiang Ren(Tongji University), Wenhua Liang(First Affiliated Hospital of Guangzhou Medical University), Yi Hu(Union Hospital), Jie Hu(Zhongshan Hospital), Ping Wang(Shenzhen Institute for Drug Control), Liyun Miao(Nanjing Drum Tower Hospital), Xin Xu(First Affiliated Hospital of Guangzhou Medical University), Yuchao Dong(Second Military Medical University), Lin Wu(Materials Systems (United States)), Ming Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Liu(Second Military Medical University), Hongmei Wang(Southeast University), Yu Chen, Zhijie Wang(Hubei University of Medicine), Kai Wang(Michigan United), Jin Yang(Affiliated Hospital of Southwest Medical University), Jie Lin(Kunming Medical University), YI Xiang-jun(Nanchang University), Gengyun Sun(Anhui Medical University), Xiaohong Xie(First Affiliated Hospital of Guangzhou Medical University), Yuehong Wang(Shanxi Agricultural University), Meng Yang(Beijing Institute of Petrochemical Technology), Ziming Li(Shanghai Jiao Tong University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenfeng Fang(Sun Yat-sen University), Shiyue Li(First Affiliated Hospital of Guangzhou Medical University), Boyan Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Wang(Dalian Medical University), Fei Xu(Sun Yat-sen University), Yihong Shen(Tongji Hospital), Qian Chu(Tongji Hospital), Hongbing Liu(Nanjing Medical University), Min Li(Central South University), Xinlin Mu(Peking University), Chunxia Su(Tongji University), Zhanhong Xie(First Affiliated Hospital of Guangzhou Medical University), Wen Dong(Hainan Medical College Hospital), Kejing Tang, Fei Cui(First Affiliated Hospital of Guangzhou Medical University), Linbo Cai(Guangdong 999 Brain Hospital), Huijuan Wang(Zhengzhou University), Gen Lin(Fujian Medical University)
Cited by 20
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
The MicroRNA Spectrum in 12 Body Fluids
|Clinical Chemistry|2010|2.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k